


PHARMACEUTICAL 2018

## AGILE THERAPEUTICS INC Rank 205 of 349









PHARMACEUTICAL 2018

## AGILE THERAPEUTICS INC Rank 205 of 349



The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 103% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 129% points.

The company's Economic Capital Ratio, given in the ranking table, is -231%, being 46% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	36,714
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,272
Liabilities, Non-Current	0
Other Assets	18
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,493
Property and Equipment	13,863
Research and Development	14,428
Revenues	0
Selling, General and Administrative Expense	12,383

Output Variable	Value in 1000 USD
Assets	50,595
Liabilities	14,272
Expenses	26,811
Stockholders Equity	36,323
Net Income	-28,304
Comprehensive Net Income	-28,304
Economic Capital Ratio	-231%

